Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DHES0815A |
Synonyms | |
Therapy Description |
DHES0815A is an antibody-drug conjugate (ADC) comprising an anti-ERBB2 (HER2) antibody linked to PBD-MA, which delivers the DNA-crosslinking agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in increased cell death (PMID: 30841523). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DHES0815A | DHES-0815A | HER2 (ERBB2) Antibody 76 HER2 (ERBB2) Antibody-Drug Conjugate 31 | DHES0815A is an antibody-drug conjugate (ADC) comprising an anti-ERBB2 (HER2) antibody linked to PBD-MA, which delivers the DNA-crosslinking agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in increased cell death (PMID: 30841523). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03451162 | Phase I | DHES0815A | Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer | Completed | USA | 1 |